Tags

Type your tag names separated by a space and hit enter

Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Br J Haematol. 2002 Feb; 116(2):383-9.BJ

Abstract

Human parvovirus B19 (B19) has been transmitted by some brands of virally attenuated plasma-derived factor VIII (FVIII) or IX (FIX) concentrates. To quantify the differences of human parvovirus B19 risk transmission between albumin-stabilized recombinant factor and plasma-derived factor, we studied the prevalence of IgG antibodies to B19 (anti-B19) in 193 haemophiliac children between 1 and 6-years of age who had previously been treated with albumin-stabilized recombinant FVIII only (n = 104), and in children previously treated with solvent/detergent high-purity non-immunopurified and non-nanofiltered FVIII or IX concentrates (n = 89). Association between the prevalence of anti-B19 and the treatment group was analysed using multivariate logistic regression. Age, severity and type of haemophilia, number of cumulative days of exposure to factor VIII or IX, previous history of red blood cells or plasma transfusion were considered as potential confounding variables. A higher prevalence of anti-B19 was found in children previously treated with solvent/detergent high-purity non-immunopurified and non-nanofiltered FVIII or IX concentrates than in children treated with albumin- stabilized recombinant FVIII only (OR: 22.3; CI: 7.9-62.8), independently of the other factors studied.

Authors+Show Affiliations

Inserm SC4, Faculté de médecine de Saint-Antoine, Paris, France. gaboulaud@b3e.jussieu.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

11841442

Citation

Gaboulaud, Valérie, et al. "Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort." British Journal of Haematology, vol. 116, no. 2, 2002, pp. 383-9.
Gaboulaud V, Parquet A, Tahiri C, et al. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol. 2002;116(2):383-9.
Gaboulaud, V., Parquet, A., Tahiri, C., Claeyssens, S., Potard, V., Faradji, A., Peynet, J., & Costagliola, D. (2002). Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. British Journal of Haematology, 116(2), 383-9.
Gaboulaud V, et al. Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort. Br J Haematol. 2002;116(2):383-9. PubMed PMID: 11841442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. AU - Gaboulaud,Valérie, AU - Parquet,Armelle, AU - Tahiri,Cedric, AU - Claeyssens,Ségolène, AU - Potard,Valérie, AU - Faradji,Albert, AU - Peynet,Jocelyne, AU - Costagliola,Dominique, AU - ,, PY - 2002/2/14/pubmed PY - 2002/3/26/medline PY - 2002/2/14/entrez SP - 383 EP - 9 JF - British journal of haematology JO - Br J Haematol VL - 116 IS - 2 N2 - Human parvovirus B19 (B19) has been transmitted by some brands of virally attenuated plasma-derived factor VIII (FVIII) or IX (FIX) concentrates. To quantify the differences of human parvovirus B19 risk transmission between albumin-stabilized recombinant factor and plasma-derived factor, we studied the prevalence of IgG antibodies to B19 (anti-B19) in 193 haemophiliac children between 1 and 6-years of age who had previously been treated with albumin-stabilized recombinant FVIII only (n = 104), and in children previously treated with solvent/detergent high-purity non-immunopurified and non-nanofiltered FVIII or IX concentrates (n = 89). Association between the prevalence of anti-B19 and the treatment group was analysed using multivariate logistic regression. Age, severity and type of haemophilia, number of cumulative days of exposure to factor VIII or IX, previous history of red blood cells or plasma transfusion were considered as potential confounding variables. A higher prevalence of anti-B19 was found in children previously treated with solvent/detergent high-purity non-immunopurified and non-nanofiltered FVIII or IX concentrates than in children treated with albumin- stabilized recombinant FVIII only (OR: 22.3; CI: 7.9-62.8), independently of the other factors studied. SN - 0007-1048 UR - https://www.unboundmedicine.com/medline/citation/11841442/Prevalence_of_IgG_antibodies_to_human_parvovirus_B19_in_haemophilia_children_treated_with_recombinant_factor__F_VIII_only_or_with_at_least_one_plasma_derived_FVIII_or_FIX_concentrate:_results_from_the_French_haemophilia_cohort_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0007-1048&date=2002&volume=116&issue=2&spage=383 DB - PRIME DP - Unbound Medicine ER -